-
Lixisenatide (trade name
Lyxumia in the
European Union and
Adlyxin in the U.S. and
manufactured by Sanofi) is a once-daily
injectable GLP-1
receptor agonist...
- glargine/
lixisenatide, sold
under the
brand name
Soliqua among others, is a fixed-dose
combination medication that
combines insulin glargine and
lixisenatide and...
-
receptor agonists : albiglutide, dulaglutide, exenatide, liraglutide,
lixisenatide, semaglutide,
tirzepatide Dipeptidyl peptidase-4 Glucose-dependent insulinotropic...
- for head lice, now
owned by
Arbor Pharmaceuticals. –
Diabetes Adlyxin (
Lixisenatide), for type 2
diabetes mellitus.
Admelog (insulin lispro), for type 1...
-
dulaglutide (Trulicity,
manufactured by Eli Lilly),
approved in 2014
lixisenatide (Lyxumia in Europe,
Adlyxin in the
United States,
manufactured by Sanofi)...
- A10AE07
Insulin icodec A10AE30
Combinations A10AE54
Insulin glargine and
lixisenatide A10AE56
Insulin degludec and
liraglutide A10AF01
Insulin (human) A10BA01...
- short-acting
Regular insulin# long-acting
Insulin detemir#
Insulin glargine# (+
lixisenatide) NPH
insulin Lente insulin‡
Ultralente insulin‡ ultra-long-acting Insulin...
- short-acting
Regular insulin# long-acting
Insulin detemir#
Insulin glargine# (+
lixisenatide) NPH
insulin Lente insulin‡
Ultralente insulin‡ ultra-long-acting Insulin...
- short-acting
Regular insulin# long-acting
Insulin detemir#
Insulin glargine# (+
lixisenatide) NPH
insulin Lente insulin‡
Ultralente insulin‡ ultra-long-acting Insulin...
-
Medication Disease Phase Partner LYXUMIA (
LIXISENATIDE) – ex-US
Diabetes Type II
Registration Sanofi LYXUMIA (
LIXISENATIDE) - US
Diabetes Type II
Phase III Sanofi...
